We wanted to share an update about PanCAN Precision Promise℠, the first adaptive clinical trial for pancreatic cancer and PanCAN’s bold initiative to accelerate new treatments for patients.

Today, FibroGen, a company testing a new investigational drug, pamrevlumab, on the Precision Promise platform trial sponsored by PanCAN, provided an update on the pamrevlumab program including the results of Precision Promise: pamrevlumab plus standard of care did not meet the primary endpoint of increasing overall survival versus standard of care. Read the press release here. While it’s disappointing when the results do not support a new treatment option for patients, the purpose of Precision Promise is to determine the effectiveness of an investigational treatment more efficiently than a standard clinical trial.

As the leading patient advocacy organization for pancreatic cancer, PanCAN is extremely proud of the leadership role we played as the sponsor of this study. Besides testing new investigational drugs, the Precision Promise platform infrastructure has already resulted in learnings related to supportive care for patients on the causes of weight loss and the importance of managing pain while treating pancreatic cancer patients.

In addition, PanCAN will make valuable clinical and molecular data from patients enrolled on Precision Promise available to researchers across the pancreatic cancer community which is a major strength of the study and is unique because pharmaceutical sponsored studies do not typically share data. Sharing data to accelerate learnings and new advances in the pancreatic cancer field is one of PanCAN’s top priorities with Precision Promise.

In January, PanCAN announced a strategic alliance with the Global Coalition for Adaptive Research (GCAR), an organization that specializes in sponsoring innovative platform clinical trials like Precision Promise. This alliance will leverage features from Precision Promise to launch the next phase of this groundbreaking effort, a new master protocol for pancreatic cancer sponsored by GCAR. Read more here.

PanCAN’s goals are to be bold, innovate, and remove barriers to accelerate progress for patients. Precision Promise reflects these goals. We are so grateful to everyone who has played a role in this groundbreaking initiative – patients, caregivers, investigators, donors, volunteers, the scientific and medical community, and industry partners. With you by our side, we are confident that we will continue to be bold and drive our collective vision to create a world in which all pancreatic cancer patients thrive.

With gratitude,

Julie Fleshman, JD, MBA
President and CEO

Anna Berkenblit, MD, MMSc
Chief Scientific and Medical Officer